Eli Lilly and Co (BUE:LLY) Cyclically Adjusted Book per Share: ARS361.18 (As of Mar. 2026)


BUE:LLY Eli Lilly and Co BUE:LLY
97 GF Score
Price ARS33,880.00
GF Value ARS38,520.27
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co Cyclically Adjusted Book per Share?

Eli Lilly and Co BUE:LLY +1.62% 97 Cyclically Adjusted Book per Share is ARS361.18 as of Mar. 2026. GuruFocus rates BUE:LLY with a GF Score™ of 97/100 and a GF Value™ of ARS38,520.27 (Modestly Undervalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Eli Lilly and Co's adjusted book value per share for the three months ended in Mar. 2026 was ARS195,287.970. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ARS361.18 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Eli Lilly and Co's average Cyclically Adjusted Book Growth Rate was 11.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 1.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 0.50% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Eli Lilly and Co was 8.80% per year. The lowest was -2.00% per year. And the median was 3.70% per year.

As of today (2026-07-03), Eli Lilly and Co's current stock price is ARS33880.00. Eli Lilly and Co's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was ARS361.18. Eli Lilly and Co's Cyclically Adjusted PB Ratio of today is 93.80.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Eli Lilly and Co was 88.29. The lowest was 5.24. And the median was 18.46.


Eli Lilly and Co  (BUE:LLY) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Eli Lilly and Co's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=33880.00/361.18
=93.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Eli Lilly and Co was 88.29. The lowest was 5.24. And the median was 18.46.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Eli Lilly and Co Cyclically Adjusted Book per Share Related Terms


Eli Lilly and Co Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Cyclically Adjusted Book per Share Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 303.65 532.28 1,511.21 260.81 358.13

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 290.66 271.09 353.06 358.13 361.18

BUE:LLY vs JNJ, ABBV, MRK: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PB Ratio falls into.


BUE:LLY
97GF Score
Eli Lilly and Co BUE:LLY
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Eli Lilly and Co's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=195287.97/330.2130*330.2130
=195,287.970

Current CPI (Mar. 2026) = 330.2130.

Eli Lilly and Co Quarterly Data

Book Value per Share CPI Adj_Book
201606 741.502 241.018 1,015.914
201609 842.577 241.428 1,152.434
201612 806.838 241.432 1,103.534
201703 784.188 243.801 1,062.133
201706 844.674 244.955 1,138.668
201709 947.893 246.819 1,268.162
201712 804.914 246.524 1,078.163
201803 1,071.491 249.554 1,417.810
201806 1,073.333 251.989 1,406.524
201809 1,803.323 252.439 2,358.909
201812 1,402.379 251.233 1,843.244
201903 399.475 254.202 518.925
201906 514.433 256.143 663.194
201909 788.168 256.759 1,013.648
201912 650.942 256.974 836.464
202003 798.802 258.115 1,021.927
202006 1,171.811 257.797 1,500.976
202009 1,498.597 260.280 1,901.246
202012 1,919.788 260.474 2,433.790
202103 2,590.705 264.877 3,229.742
202106 2,552.763 271.696 3,102.569
202109 3,171.603 274.310 3,817.960
202112 3,803.523 278.802 4,504.891
202203 4,215.708 287.504 4,841.956
202206 4,328.429 296.311 4,823.660
202209 5,890.447 296.808 6,553.402
202212 7,516.182 296.797 8,362.419
202303 9,315.235 301.836 10,191.003
202306 11,188.647 305.109 12,109.235
202309 16,545.086 307.789 17,750.480
202312 17,294.829 306.746 18,617.936
202403 47,953.046 312.332 50,698.357
202406 53,951.821 314.175 56,705.953
202409 60,165.980 315.301 63,011.499
202412 64,241.015 315.605 67,214.456
202503 74,881.408 319.799 77,319.861
202506 96,759.231 322.561 99,054.616
202509 144,273.962 324.800 146,678.380
202512 172,173.716 324.054 175,446.065
202603 195,287.970 330.213 195,287.970

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of ARS361.18 mean?
Eli Lilly and Co (BUE:LLY) has a Cyclically Adjusted Book per Share of ARS361.18 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's Cyclically Adjusted Book per Share too high?
Eli Lilly and Co's current Cyclically Adjusted Book per Share is ARS361.18. Overall, Eli Lilly and Co has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Cyclically Adjusted Book per Share compare to JNJ and ABBV?
Eli Lilly and Co's Cyclically Adjusted Book per Share of ARS361.18 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current Cyclically Adjusted Book per Share is ARS361.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (BUE:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is ARS38,520.27, compared to a current price of ARS33,880.00 — trading 12% below its estimated fair value. The current Cyclically Adjusted Book per Share is ARS361.18. Eli Lilly and Co's overall GF Score™ is 97/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Eli Lilly and Co (BUE:LLY), the current Cyclically Adjusted Book per Share is ARS361.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (BUE:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of ARS33,880.00 is trading 12% below its estimated GF Value™ of ARS38,520.27. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for BUE:LLY:

  • Cyclically Adjusted Book per Share: ARS361.18
  • GF Value™: ARS38,520.27 vs. price of ARS33,880.00 (12% below fair value)
  • GF Score™: 97/100 with 6 warning signs

No single metric tells the full story. See the BUE:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
97GF Score

Get the complete analysis for BUE:LLY

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS33,880.00
Price
ARS38,520.27
GF Value